Quoin Pharmaceuticals Ltd. provided a clinical and regulatory update for its QRX009 topical rapamycin development programs. The Company is planning to initiate several investigator-led clinical studies for its QRX009 topical rapamycin lotion in a number of key target indications. The first study will be in Pachyonychia Congenita (PC), a rare skin disease with no approved treatments or cure. This study will be led by Professor Edel O?Toole of Queen Mary University of London, a globally recognized clinician and thought-leader in PC who has previous experience in clinical trials for PC.

The Company is targeting initiating this study in the third quarter of this year. In addition, Quoin Pharmaceuticals Ltd. is planning to initiate investigator-led clinical studies in both Gorlin Syndrome (GS) and Tuberous Sclerosis Complex (TSC) later this year. Finally, Quoin Pharmaceuticals Ltd. is on track to submit an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for QRX009 for an additional indication in the third quarter of this year.